BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12367647)

  • 1. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence.
    Lehmann HW; Kühner L; Beckenlehner K; Müller-Godeffroy E; Heide KG; Küster RM; Modrow S
    J Clin Virol; 2002 Aug; 25(2):135-43. PubMed ID: 12367647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection.
    Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S
    Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood.
    Lehmann HW; Knöll A; Küster RM; Modrow S
    Arthritis Rheum; 2003 Jun; 48(6):1631-8. PubMed ID: 12794831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women.
    Hemauer A; Gigler A; Searle K; Beckenlehner K; Raab U; Broliden K; Wolf H; Enders G; Modrow S
    J Med Virol; 2000 Jan; 60(1):48-55. PubMed ID: 10568763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
    Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
    J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses in parvovirus B19 infected patients.
    Modrow S; Dorsch S
    Pathol Biol (Paris); 2002 Jun; 50(5):326-31. PubMed ID: 12116851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen.
    Heegaard ED; Rasksen CJ; Christensen J
    J Med Virol; 2002 Jul; 67(3):375-83. PubMed ID: 12116031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of parvovirus B19-specific antibodies and of viral DNA in patients with endogenous uveitis.
    Heinz C; Plentz A; Bauer D; Heiligenhaus A; Modrow S
    Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):999-1004. PubMed ID: 15906067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term follow up of serostatus after maternofetal parvovirus B19 infection.
    Dembinski J; Eis-Hübinger AM; Maar J; Schild R; Bartmann P
    Arch Dis Child; 2003 Mar; 88(3):219-21. PubMed ID: 12598382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.
    Manaresi E; Zuffi E; Gallinella G; Gentilomi G; Zerbini M; Musiani M
    J Med Virol; 2001 May; 64(1):67-73. PubMed ID: 11285571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent parvovirus B19 infections in immunocompromised children.
    Flunker G; Peters A; Wiersbitzky S; Modrow S; Seidel W
    Med Microbiol Immunol; 1998 Mar; 186(4):189-94. PubMed ID: 9574901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
    Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
    J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis.
    Zakrzewska K; Azzi A; De Biasi E; Radossi P; De Santis R; Davoli PG; Tagariello G
    J Med Virol; 2001 Oct; 65(2):402-7. PubMed ID: 11536251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG.
    Kerr S; O'Keeffe G; Kilty C; Doyle S
    J Med Virol; 1999 Feb; 57(2):179-85. PubMed ID: 9892405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
    Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
    J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of functional B cell memory against parvovirus B19 capsid proteins may be associated with resolution of persistent infection.
    Corcoran A; Crowley B; Dewhurst C; Pizer BL; Doyle S
    J Med Virol; 2006 Jan; 78(1):125-8. PubMed ID: 16299723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection.
    Pereira RF; Paula WN; Cubel Rde C; Nascimento JP
    Mem Inst Oswaldo Cruz; 2001 May; 96(4):507-13. PubMed ID: 11391423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baculovirus expression of parvovirus B19 (B19V) NS1: utility in confirming recent infection.
    Ennis O; Corcoran A; Kavanagh K; Mahon BP; Doyle S
    J Clin Virol; 2001 Aug; 22(1):55-60. PubMed ID: 11418353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of B-cell epitopes on human parvovirus B19 non-structural and structural proteins.
    Tolfvenstam T; Lundqvist A; Levi M; Wahren B; Broliden K
    Vaccine; 2000 Nov; 19(7-8):758-63. PubMed ID: 11115697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of antibodies to human parvovirus B19 nonstructural protein in persons with various clinical outcomes following B19 infection.
    Jones LP; Erdman DD; Anderson LJ
    J Infect Dis; 1999 Aug; 180(2):500-4. PubMed ID: 10395869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.